08:00 , Dec 4, 2006 |  BioCentury  |  Finance

Ebb & Flow

ConjuChem (TSX:CJB) recently disclosed positive Phase I/II data for PC-DAC: Exendin-4 , a once-weekly therapeutic to treat diabetes. But the company was in a bind. It only had C$19 million ($16.7 million) in cash at...
23:03 , Nov 22, 2006 |  BC Extra  |  Financial News

Orexigen raises $30 million

Orexigen (San Diego, Calif.) raised $30 million in a series C round. MPM BioEquities and Wasatch Advisors joined existing investors Domain Associates; Kleiner Perkins Caufield & Byers; Sofinnova Ventures; Bank of America Ventures; Montreux Equity...
08:00 , Dec 11, 2000 |  BioCentury  |  Finance

Lump of coal in Euronext stocking

As stock exchanges increasingly move towards 24-7 trading, Euronext - the planned merger of the Paris, Brussels and Amsterdam exchanges - is moving in the opposite direction, proposing a twice-a-day auction system for listed stocks...
08:00 , Mar 14, 2000 |  BC Extra  |  Financial News

Seattle Genetics raises $30 million

Bank of America Ventures led the venture financing, which will help fund the company's clinical trials of monoclonal antibodies for cancer. Other investors included Cascade Investment; Vulcan Ventures; Olympic Venture Partners; Sofinnova Ventures; and Indosuez...
08:00 , Jan 17, 2000 |  BioCentury  |  Finance

Manic Monday

The BioCentury 100 index rocketed 392.6 points (19 percent) to 2417.81 on Monday, the first day of the Chase H&Q Healthcare Conference, with genomics frenzy pacing the sector. Big winners included Genome Therapeutics (GENE), up...